Federal Response to COVID-19: Therapeutics Clinical Implementation Guide

Outpatient Administration Guide for Healthcare Providers
September 2023

Unclassified
# Table of Contents

<table>
<thead>
<tr>
<th>Reference Guide:</th>
<th>Topics:</th>
<th>Slide:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Module 1</td>
<td>COVID-19 Outpatient Therapeutics Overview</td>
<td>Slide 6</td>
</tr>
<tr>
<td>Module 2</td>
<td>Product Information&lt;br&gt;• Preferred Outpatient Therapies&lt;br&gt;• Alternate Outpatient Therapies</td>
<td>Slide 17</td>
</tr>
<tr>
<td>Module 3</td>
<td>Oral Antiviral Administration</td>
<td>Slide 57</td>
</tr>
<tr>
<td>Module 4</td>
<td>Reimbursement</td>
<td>Slide 61</td>
</tr>
<tr>
<td>Module 5</td>
<td>Additional Resources</td>
<td>Slide 64</td>
</tr>
<tr>
<td>Module 6</td>
<td>Appendices</td>
<td>Slide 68</td>
</tr>
<tr>
<td></td>
<td>Appendix A: Outpatient Infusion Site Resources</td>
<td>Slide 69</td>
</tr>
<tr>
<td></td>
<td>Appendix B: COVID-19 Convalescent Plasma</td>
<td>Slide 73</td>
</tr>
<tr>
<td></td>
<td>Appendix C: Formerly-Authorized Products</td>
<td>Slide 77</td>
</tr>
</tbody>
</table>
Clinical Implementation Guide Objectives

• Review available outpatient COVID-19 therapeutics used to treat eligible non-hospitalized patients who have mild to moderate symptoms of COVID-19.
• Summarize key information on COVID-19 therapeutics and support healthcare providers’ understanding of these therapies and how to implement their administration.
• Describe process for obtaining and reporting COVID-19 therapeutics products purchased by HHS/ASPR, including collaboration with state and territorial health departments, as well as national healthcare and medical organizations and associations to ensure efficient and equitable distribution.

IMPORTANT NOTE: The Clinical Implementation Guide is updated regularly following changes to COVID-19 therapeutic Emergency Use Authorizations (EUAs), approvals, or prescribing information of FDA approved therapeutics; however, there may be a lag in publishing updated versions. As such, it is important for healthcare providers to stay abreast of the latest changes to EUAs and prescribing information and their impact on distribution, and administration of COVID-19 therapeutics.

See the latest information on all FDA authorized products under EUA https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization
COVID-19 Therapeutics under Emergency Use Authorization (EUA)

• In certain types of emergencies, the FDA can issue an emergency use authorization (EUA), to provide more timely access to critical medical products (including medicines and tests) that may help during the emergency when there are no adequate, approved, and available alternative options.

• The EUA process is different than FDA approval, clearance, or licensing because the EUA standard may permit authorization based on significantly less data than would be required for approval, clearance, or licensing by the FDA. This enables the FDA to authorize the emergency use of medical products that meet the criteria within weeks rather than months to years. Since EUA products are not approved and, thus, do not have labeled indications, “off-label use” or the use of the product outside of the EUA authorization is not permitted.

• EUAs are in effect until the emergency declaration ends but can be revised or revoked. The need will be evaluated during the emergency, availability of new data on the product’s safety and effectiveness, or as products meet the criteria to become approved, cleared, or licensed by the FDA.

• Products packaged under the EUA must be prescribed/administered in accordance with the EUA even if the product receives FDA approval
HHS’s COVID-19 Therapeutics Homepage & Announcements

ASPR’s Response to COVID-19 website
https://aspr.hhs.gov/COVID-19/Pages/default.aspx

New and Notable: COVID-19 Therapeutics Announcements
https://aspr.hhs.gov/COVID-19/Therapeutics/Pages/default.aspx
Module 1: COVID-19 Outpatient Therapeutics Overview
Who Is At Risk for Severe COVID-19?

COVID-19 Risk Continuum

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>LOWER RISK</th>
<th>HIGHER RISK</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;30</td>
<td>None</td>
<td>3+</td>
</tr>
<tr>
<td>30–49</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>50–69</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>≥70</td>
<td>3+</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Medical Conditions</th>
<th>LOWER RISK</th>
<th>HIGHER RISK</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;30</td>
<td>None</td>
<td>3+</td>
</tr>
<tr>
<td>30–49</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>50–69</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>≥70</td>
<td>3+</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Vaccination Status</th>
<th>LOWER RISK</th>
<th>HIGHER RISK</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;30</td>
<td>None</td>
<td>3+</td>
</tr>
<tr>
<td>30–49</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>50–69</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>≥70</td>
<td>3+</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Immunosuppression</th>
<th>LOWER RISK</th>
<th>HIGHER RISK</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;30</td>
<td>None</td>
<td>3+</td>
</tr>
<tr>
<td>30–49</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>50–69</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>≥70</td>
<td>3+</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sociodemographic factors and non-pharmaceutical interventions affect exposure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original illustration by Dr. William Werbel, adapted for the COVID-19 Real-Time Learning Network</td>
</tr>
</tbody>
</table>

Summary of COVID-19 Preventative Agents & Treatments

No Illness
- Baseline health status, no infection

Exposed
- Per CDC Close Contact Criteria

Mild to Moderate Symptoms
- Not hospitalized for COVID

Hospital Admission
- Hosp. for reason other than COVID
- Hospitalized for COVID, not on oxygen
- Hospitalized, on oxygen

ICU Admission
- Hospitalized, high flow oxygen/ non-invasive ventilation
- Hospitalized, mechanical ventilation/ ECMO

**COVID19 Vaccines**
- None currently authorized for use in any U.S. state or territory.

*Oral Antivirals*
- Paxlovid (nirmatrelvir + ritonavir, Pfizer)
- Lagevrio (molnupiravir, Merck) – Alternative

**IV Antiviral**
- Veklury® (remdesivir, Gilead)

1 ConVAlescent Plasma EUA https://www.fda.gov/media/141478/download
High titer convalescent plasma is authorized for specific immunocompromised patients.

2 Refer to individual product Fact Sheets for authorization details

Please see NIH Current Inpatient Therapies (https://www.covid19treatmentguidelines.nih.gov/therapies/)

There is ample supply of COVID-19 therapeutics; every eligible patient should have access to these medications

*HzHS distribution; USG distribution will continue beyond PHE
**Commercially available

Be sure to check latest updates on inpatient care
Therapeutic Management of Nonhospitalized Adults With COVID-19
Therapeutic Management of Hospitalized Adults With COVID-19
• The COVID-19 Treatment Guidelines Panel (the Panel) recommends the following anti-SARS-CoV-2 therapies as preferred treatments for COVID-19. These drugs are listed in order of preference:
  ▪ Nirmatrelvir co-packaged with ritonavir (Paxlovid) (Alla)
  ▪ Remdesivir (Veklury) (BIIa)
• Alternative therapy. For use when the preferred therapies are not available, feasible to use, or clinically appropriate.
  ▪ Molnupiravir (Lagevrio) (CIIa)
NIH: Patient Prioritization for Treatment¹

• These guidelines¹ are for use only when logistical constraints limit the availability of therapies.

• Remdesivir is a recommended option if nirmatrelvir co-packaged with ritonavir cannot be used.

• Some treating facilities may not have the ability to provide a 3-day course of remdesivir intravenous infusions to all eligible patients. In these situations, prioritizing patients who will benefit the most from the therapy becomes necessary.

• Prioritization strategy includes 4 factors: age, vaccination status, immune status, and clinical risk factors.

¹NIH Prioritization Guidelines https://www.covid19treatmentguidelines.nih.gov/overview/prioritization-of-therapeutics/
## NIH: Patient Prioritization for Treatment

<table>
<thead>
<tr>
<th>Tier</th>
<th>Risk Group</th>
</tr>
</thead>
</table>
| 1    | - Immunocompromised individuals not expected to mount an adequate immune response to COVID-19 vaccination or SARS-CoV-2 infection due to their underlying conditions, regardless of vaccine status (see Immunocompromising Conditions below); or  
- Unvaccinated individuals at the highest risk of severe disease (anyone aged ≥75 years or anyone aged ≥65 years with additional risk factors). |
| 2    | - Unvaccinated individuals not included in Tier 1 who are at risk of severe disease (anyone aged ≥65 years or anyone aged <65 years with clinical risk factors) |
| 3    | - Vaccinated individuals at risk of severe disease (anyone aged ≥65 years or anyone aged <65 years with clinical risk factors)  
**Note:** Vaccinated individuals who are not up to date with their immunizations are likely at higher risk for severe disease; patients within this tier who are in this situation should be prioritized for treatment. |

---

1. NIH Prioritization Guidelines [https://www.covid19treatmentguidelines.nih.gov/overview/prioritization-of-therapeutics/]
Recommendations for Special Populations: Immunocompromised & Pediatrics
NIH Guidelines for Patients Who are Immunocompromised

• All people who are moderately or severely immunocompromised should receive COVID-19 vaccination.

• All close contacts of people who are immunocompromised are strongly encouraged to be up to date on vaccination against COVID-19.

• There is insufficient evidence for recommendation for or against the use of SARS-CoV-2 serologic testing to assess for immunity or to guide clinical decision about using COVID-19 vaccines or PrEP for certain people.

• COVID-19 in individuals who are moderately to severely immunocompromised
  ▪ Patients should be treated quickly with appropriate COVID-19 therapeutics
  ▪ Decisions regarding stopping or reducing the doses of immunosuppressive drugs in patients with COVID-19 should be made in consultation with the appropriate specialists; clinicians should consider factors such as the underlying disease, the specific immunosuppressants being used, the potential for drug-drug interactions, and the severity of COVID-19

Veklury (Remdesivir)

- Pediatric patients **28 Days of Age and Older and weighing 3 kg to less than 40 kg**

* Pediatric patients less than 12 years of age but weighing 40kg or greater receive Veklury at the adult dose

NIH Guidelines For Therapeutic Management in Non-hospitalized Children With COVID-19

<table>
<thead>
<tr>
<th>Risk of Severe COVID-19</th>
<th>Panel’s Recommendations</th>
<th>Aged 12-17 years</th>
<th>Aged &lt;12 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptomatic, Regardless of Risk Factors</td>
<td>• Provide supportive care (AIII).</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Provide supportive care (AIII).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>High Risk(^a,b)</td>
<td>• Use 1 of the following options (listed in order of preference):(^c)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>▪ Nirmatrelvir co-packaged with ritonavir (Paxlovid) within 5 days of symptom onset (BIII)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>▪ Remdesivir within 7 days of symptom onset (CIII)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Nirmatrelvir co-packaged with ritonavir is not authorized by the FDA for use in children aged &lt;12 years.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• There is insufficient evidence to recommend either for or against the routine use of remdesivir. Consider treatment based on age and other risk factors.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intermediate Risk(^b,d)</td>
<td>• There is insufficient evidence to recommend either for or against the use of any antiviral therapy. Consider treatment based on age and other risk factors.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• There is insufficient evidence to recommend either for or against the use of any antiviral therapy. Consider treatment based on age and other risk factors.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low Risk(^b,e)</td>
<td>• Manage with supportive care alone (BIII).</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Manage with supportive care alone (BIII).</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\(^a\) Molnupiravir is not authorized by the FDA for use in children aged <18 years and should not be used.

\(^b\) See Table 3b for the Panel’s framework for assessing the risk of progression to severe COVID-19 based on patient conditions and COVID-19 vaccination status.

\(^c\) Initiate treatment as soon as possible after symptom onset.

\(^d\) The relative risk of severe COVID-19 for intermediate-risk patients is lower than the risk for high-risk patients but higher than the risk for low-risk patients.

\(^e\) Low-risk patients include those with comorbid conditions that have a weak or unknown association with severe COVID-19. Patients with no comorbidities are included in this group.

Additional Tools to Assist in COVID-19 Outpatient Therapeutic Selection

- NIH’s COVID-19 Treatment Guidelines - What’s new

- NIH Therapeutic Management of Nonhospitalized Children With COVID-19

- CDC Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19: Information for Healthcare Professionals

- CDC COVID Data Tracker
  https://covid.cdc.gov/covid-data-tracker/#variant-proportions
  The CDC monitors and publishes variant information: https://covid.cdc.gov/covid-data-tracker/#variant-proportions

- Clinical Decision Aid

- Side-by-Side Overview of Outpatient Therapeutics

- ASPR COVID-19 Therapeutics
  https://aspr.hhs.gov/COVID-19/Therapeutics/Pages/default.aspx
Module 2:
Product Information
Products for Treatment of Mild-to-Moderate COVID-19: Preferred Therapies per NIH Guidelines
Paxlovid (nirmatrelvir co-packaged with ritonavir) – Pfizer Oral Antiviral (Preferred)*

*Note currently available product is still labeled under EUA

Fact Sheet for Healthcare Providers for Paxlovid (nirmatrelvir co-packaged with ritonavir) https://www.fda.gov/media/155050/download
Paxlovid (nirmatrelvir co-packaged with ritonavir)
Product Information

• FDA Fact Sheets and Prescribing Information
  - Paxlovid provider fact sheet https://www.fda.gov/media/155050/download
  - Fact Sheet for Patients, Parents and Caregivers https://www.fda.gov/media/155051/download

• Manufacturer’s Resources:

• Prescribing Resources:
  - Paxlovid Patient Eligibility Screening Checklist Tool for Prescribers https://www.fda.gov/media/158165/download
  - Important Prescribing and Dispensing Information https://www.fda.gov/media/155071/download
  - University of Liverpool COVID-19 Drug Interactions Checker https://covid19-druginteractions.org

• Safety Reporting:
  - Pfizer Safety Reporting http://www.pfizersafetyreporting.com/
Paxlovid (nirmatrelvir co-packaged with ritonavir)
Emergency Use AUTHORIZATION

• Paxlovid EUA authorized for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg), who are at high risk for progression to severe COVID-19, including hospitalization or death

• Initiated as soon as possible after diagnosis of COVID-19 and within 5 days of symptom onset.

• Paxlovid includes: nirmatrelvir (a SARS-CoV-2 main proteases inhibitor) co-packaged with ritonavir (a CYP34A inhibitor)

• PAXLOVID is not authorized for use as pre-exposure or post-exposure prophylaxis for prevention of COVID-19

• Paxlovid (nirmatrelvir co-packaged with ritonavir) may be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under state law to prescribe drugs in the therapeutic class to which Paxlovid (nirmatrelvir co-packaged ritonavir) belongs (i.e., anti-infectives). Pharmacists are also authorized under the EUA to prescribe Paxlovid under certain conditions

Fact Sheet for Healthcare Providers for Paxlovid (nirmatrelvir co-packaged with ritonavir) https://www.fda.gov/media/155050/download
Paxlovid (nirmatrelvir co-packaged with ritonavir)
FDA APPROVAL

- On May 25, 2023, [FDA approved a New Drug Application (NDA) for Paxlovid](https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-antiviral-treatment-covid-19-adults) for the treatment of mild to moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death
  - [Paxlovid Prescribing Information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217188s000lbl.pdf)
- The Emergency Use Authorization (EUA) continues to authorize Paxlovid to treat certain eligible pediatric patients, a patient population that is not covered under the approved NDA for Paxlovid at this time
- Paxlovid also remains authorized under EUA to ensure continued access for all eligible patients to the current supply of Paxlovid, including adult patients
  - [EUA fact sheet for health care providers](https://www.fda.gov/media/155050/download)
- The product packaged under EUA – which contains the same tablets (nirmatrelvir tablets and ritonavir tablets) as the Paxlovid that is now FDA-approved – continues to be available from the federal government at no cost
Paxlovid labeled under the EUA may also be prescribed for an individual patient by a state-licensed pharmacist under the following conditions:

- Sufficient information is available, such as through access to health records less than 12 months old or consultation with a health care provider in an established provider-patient relationship with the individual patient, to assess renal and hepatic function; and

- Sufficient information is available, such as through access to health records, patient reporting of medical history, or consultation with a health care provider in an established provider-patient relationship with the individual patient, to obtain a comprehensive list of medications (prescribed and non-prescribed) that the patient is taking to assess for potential drug interaction.

Fact Sheet for Healthcare Providers for Paxlovid (nirmatrelvir co-packaged with ritonavir) https://www.fda.gov/media/155050/download
Paxlovid (nirmatrelvir co-packaged with ritonavir) – Pharmacist Prescribing Authorization under EUA

The state-licensed pharmacist should refer an individual patient for clinical evaluation (e.g., telehealth, in-person visit) with a physician, advanced practice registered nurse, or physician assistant licensed or authorized under state law to prescribe drugs, if any of the following apply:

• Sufficient information is not available to assess renal and hepatic function.
• Sufficient information is not available to assess for a potential drug interaction.
• Modification of other medications is recommended due to a potential drug interaction.
• Paxlovid is not an appropriate therapeutic option based on the authorized Fact Sheet for Healthcare Providers or due to potential drug interactions for which recommended monitoring would not be feasible.

Fact Sheet for Healthcare Providers for Paxlovid (nirmatrelvir co-packaged with ritonavir) https://www.fda.gov/media/155050/download
Dosage and Administration

- **eGFR ≥ 60 mL/min:** 300 mg nirmatrelvir (two 150 mg tablets) co-packaged with 100 mg ritonavir (one 100 mg tablet) taken together twice daily for 5 days.

- **Dose reduction for moderate renal impairment eGFR > 30 mL/min to < 60 mL/min:** 150 mg nirmatrelvir (one 150 mg tablet) co-packaged with 100 mg ritonavir (one 100 mg tablet) taken together twice daily for 5 days.

- **eGFR <30 mL/min:** currently not recommended

- **Severe hepatic impairment (Child-Pugh Class C):** currently not recommended

Contraindications and Precautions

- History of clinically significant hypersensitivity reactions to the active ingredients or any other components.

- Co-administration with drugs highly dependent on CYP3A for clearance may result in life-threatening reactions.1

- Co-administration with potent CYP3A inducers may result in reduced nirmatrelvir plasma concentrations and potential loss of virologic response.

- The concomitant use of Paxlovid (nirmatrelvir co-packaged with ritonavir) and certain other drugs may result in potentially significant drug interactions.

- Hepatic transaminase elevations, hypersensitivity reactions, clinical hepatitis, and jaundice have occurred in patients receiving ritonavir.

- Paxlovid (nirmatrelvir co-packaged with ritonavir) use may lead to a risk of HIV-1 developing resistance to HIV protease inhibitors in individuals with uncontrolled or undiagnosed HIV-1 infection.

---

1 Liverpool Covid-19 interaction checker https://covid19-druginteractions.org/
Fact Sheet for Healthcare Providers for Paxlovid (nirmatrelvir co-packaged with ritonavir) https://www.fda.gov/media/155050/download
Paxlovid (nirmatrelvir co-packaged with ritonavir) Patient Eligibility Screening Checklist Tool for Prescribers

**Medical History**

- Mild to moderate COVID-19 with symptom onset within 5 days
- Age ≥ 12 years of age and weighing at least 40 kg (if utilizing product under EUA)
- Adult (if utilizing approved product)
- Has one or more risk factors for progression to severe COVID-19
- Not requiring hospitalization due to severe or critical COVID-19 at treatment initiation
- No known or suspected severe renal impairment (eGFR < 30 mL/min)
  - Note that a dose reduction is required for patients with moderate renal impairment (eGFR ≥30-<60 mL/min); see the Fact Sheet for Healthcare Providers.
- No known or suspected severe hepatic impairment
- No history of clinically significant hypersensitivity reactions to the active ingredients (nirmatrelvir or ritonavir) or other components of the product

---

Fact Sheet for Healthcare Providers for Paxlovid (nirmatrelvir co-packaged with ritonavir): [https://www.fda.gov/media/155050/download](https://www.fda.gov/media/155050/download)
See table in Paxlovid Patient Eligibility Screening Checklist Tool for Prescribers: [https://www.fda.gov/media/158165/download](https://www.fda.gov/media/158165/download)
Paxlovid (nirmatrelvir co-packaged with ritonavir) Patient Eligibility Screening Checklist Tool for Prescribers (continued)

Concomitant Medications

- **Assess patient’s home medication list for drug-drug interactions**
- See table in [Paxlovid Patient Eligibility Screening Checklist Tool for Prescribers](https://www.fda.gov/media/158165/download)
- **HMG-CoA reductase inhibitors (statins)**
  - Patient is taking lovastatin or simvastatin, which are contraindicated with Paxlovid coadministration: The statin can be held 12 hours prior to the first dose of Paxlovid treatment, held during the 5 days of treatment, and restarted 5 days after completing Paxlovid.
  - Patient is taking atorvastatin or rosuvastatin: Temporary discontinuation of atorvastatin and rosuvastatin during treatment with Paxlovid should be considered depending on statin dose. Atorvastatin and rosuvastatin do not need to be held prior to or after completing Paxlovid.
- **Hormonal contraceptives containing ethinyl estradiol**: Patient is taking a hormonal contraceptive containing ethinyl estradiol: The need for an additional non-hormonal method of contraception during the 5 days of Paxlovid treatment and until one menstrual cycle after stopping Paxlovid should be recommended.
- **Medications for HIV-1 Treatment**: Patient is taking medications for the treatment of HIV-1 infection: With the exception of maraviroc, HIV antiretroviral medications can be co-administered with Paxlovid without dose adjustment, but arranging follow-up by the HIV care provider to monitor for side effects is recommended.

Other Drugs with Established and Other Potentially Significant Drug Interactions with Paxlovid

- See table in [Paxlovid Patient Eligibility Screening Checklist Tool for Prescribers](https://www.fda.gov/media/158165/download)

*Prescriber is encouraged to include a note to the pharmacist in the prescription stating:

Please fill prescription by [insert date]. This prescription fill by date is within 5 days from symptom onset and complies with the patient eligibility criteria under the EUA.*
Paxlovid (nirmatrelvir co-packaged with ritonavir) Patient Eligibility Screening Checklist Tool for Prescribers (Table)

See table in Paxlovid Patient Eligibility Screening Checklist Tool for Prescribers: https://www.fda.gov/media/158165/download
Additional Paxlovid (nirmatrelvir co-packaged with ritonavir) Prescribing Resources

- University of Liverpool COVID-19 Drug Interactions
  https://covid19-druginteractions.org/checker

- FDA PAXLOVID Patient Eligibility Screening Checklist Tool for Prescribers
  https://www.fda.gov/media/158165/download

- Pfizer Drug Interaction Checker
  https://www.pfizermedicalinformation.com/en-us/drug-interactionchecker?product=PAXLOVID%E2%84%A2+%7C+nirmatrelvir+tablets%3B+ritonavir+tablets&product2=Alfuzosin

- NIH COVID-19 Treatment Guidelines – Nirmatrelvir Co-Packaged with Ritonavir (Paxlovid)
Paxlovid (nirmatrelvir co-packaged with ritonavir)
Formulation and Packaging – EUA Product

**Standard Dose**
300 mg nirmatrelvir; 100 mg ritonavir: Each carton contains 30 tablets divided in 5 daily dose blister cards. Each blister card contains 4 nirmatrelvir tablets (150 mg each) and 2 ritonavir tablets (100 mg each). Nirmatrelvir tablets and ritonavir tablets are supplied in separate blister cavities within the same child-resistant blister card.

**Reduced Dose (Renal)**
150 mg nirmatrelvir; 100 mg ritonavir: Each carton contains 20 tablets divided in 5 daily dose blister cards. Each blister card contains 2 nirmatrelvir tablets (150 mg each) and 2 ritonavir tablets (100 mg each). Nirmatrelvir tablets and ritonavir tablets are supplied in separate blister cavities within the same child-resistant blister card.

Viral RNA Rebound

- Post-treatment increases in SARS-CoV-2 RNA levels (i.e., viral RNA rebound) in nasopharyngeal samples were observed on Day 10 and/or Day 14 in a subset of Paxlovid and placebo recipients, irrespective of COVID-19 symptoms. The frequency of detection of post-treatment viral RNA rebound varied according to analysis parameters but was generally similar among Paxlovid and placebo recipients, regardless of the rebound definition used. A similar or smaller percentage of placebo recipients compared to Paxlovid recipients had nasopharyngeal viral RNA results < LLOQ (lower limit of quantitation) at all study timepoints in both the treatment and post-treatment periods.

- Post-treatment viral RNA rebound was not associated with the primary clinical outcome of COVID-19-related hospitalization or death from any cause through Day 28 following the single 5-day course of Paxlovid treatment. Post-treatment viral RNA rebound also was not associated with drug resistance as measured by Mpro sequencing. The clinical relevance or exact incidence of post-treatment increases in viral RNA following Paxlovid or placebo treatment is unknown at this time.

- Viral RNA rebound is not specific to Paxlovid or Lagevrio and has been seen in placebo recipients.

***Not exclusive to Paxlovid***

Paxlovid (nirmatrelvir co-packaged with ritonavir)
Product Information & Ordering Logistics

- **EUA Status:** Distributed product is currently under Emergency Use authorization (EUA)
- **Procurement:** Purchased and supplied by the US Government (Product under EUA)
- **Eligibility information for product labeled under EUA:**
  - ASPR Paxlovid page [https://aspr.hhs.gov/COVID-19/Therapeutics/Products/Paxlovid/Pages/default.aspx](https://aspr.hhs.gov/COVID-19/Therapeutics/Products/Paxlovid/Pages/default.aspx)
  - HHS Information Sheet for Providers – Paxlovid [https://aspr.hhs.gov/COVID-19/Therapeutics/Products/Paxlovid/Documents/paxlovid-information-sheet.pdf](https://aspr.hhs.gov/COVID-19/Therapeutics/Products/Paxlovid/Documents/paxlovid-information-sheet.pdf)
  - Frequently Asked Questions: FDA EUA for Paxlovid (FDA) [https://www.fda.gov/media/155052/download](https://www.fda.gov/media/155052/download)
- **Indications and usage for product labeled under FDA approval**
- **To order:**
- **Where to find:**
  - COVID-19 Test to Treat Locator [https://aspr.hhs.gov/TestToTreat/Pages/default.aspx](https://aspr.hhs.gov/TestToTreat/Pages/default.aspx)
Veklury (remdesivir) – Gilead Antiviral for IV Infusion (Preferred)

Veklury Product Information
https://www.vekluryhcp.com/
Veklury (remdesivir) Product Information

• Prescribing Information & FDA Fact Sheets

• Manufacturer’s Resources:
  ▪ Website for Healthcare Providers https://www.vekluryhcp.com/
  ▪ Website for Patients https://www.veklury.com/

• Safety Reporting:
  ▪ Safety Reporting Email Safety_fc@gilead.com
  ▪ Report a Pregnancy Exposure https://covid-pr.pregistry.com
Veklury (remdesivir) – Outpatient Use

- FDA approved Veklury (remdesivir) for certain non-hospitalized adults and pediatric patients for treatment of mild-to-moderate COVID-19, including:
  - Adults and pediatric patients 28 days of age and older and weighing at least 3 kg, AND
  - Who are not hospitalized and have mild-to-moderate COVID-19 and are at high risk for progression to severe COVID-19, including hospitalization or death
- The treatment course of Veklury (remdesivir) should be initiated as soon as possible after diagnosis of symptomatic COVID-19 has been made and within 7 days of symptom onset. The recommended total duration of treatment for non-hospitalized patients is 3 days.
- No dosage adjustment of Veklury is recommended in patients with any degree of renal impairment, including those on dialysis for adult and pediatric patients
  - Veklury may be administered without regard to the timing of dialysis in all patients
- No dosage adjustment of Veklury is recommended for patients with mild, moderate, or severe hepatic impairment (Child-Pugh Class A, B, or C)
  - The label still recommends:
    - Initial hepatic laboratory testing in all patients, before starting Veklury and during treatment as clinically appropriate
    - Discontinuation be considered if alanine transaminase (ALT) levels increase to 10 times the upper limit of normal or if ALT elevation is accompanied by signs or symptoms of liver inflammation.

Veklury (remdesivir)

Dosage and Administration

• Dosage:
  - For adults and pediatric patients who weight > 40 kg: 200 mg on Day 1, followed by once-daily maintenance doses of 100 mg from Day 2 administered only via intravenous infusion over 30 to 120 minutes
  - For pediatric patients 28 days of age and older and weighing 3 kg to less than 40 kg: 5 mg/kg on Day 1 followed by 2.5 mg/kg once daily from Day 2

• Dosage Forms:
  - For injection: 100 mg of remdesivir as a lyophilized powder, in a single-dose vial
  - Injection: 100 mg/20 mL (5 mg/mL) remdesivir, in a single-dose vial

Contraindications and Precautions

• Contraindications
  - History of clinically significant hypersensitivity reactions to Veklury or any components of the product
  - Hypersensitivity including infusion-related and anaphylactic reactions

• Pre-administration testing
  - Perform hepatic laboratory testing in all patients before starting Veklury and during treatment as clinically appropriate
  - Assess prothrombin time before starting Veklury and monitor as clinically appropriate

• Increased risk of transaminase elevations with administration
• Risk of reduced antiviral activity when co-administered with chloroquine phosphate or hydroxychloroquine sulfate
Veklury (remdesivir) Pediatric Eligibility Criteria

- Pediatric patients **28 Days of Age and Older and weighing 3 kg to less than 40 kg***
- Mild-to-moderate COVID-19 and at high risk for progression to severe disease
- Initiate within **7 days of symptom onset**

* Pediatric patients less than 12 years of age but weighing 40kg or greater receive Veklury at the adult dose

Veklury (remdesivir) Pediatric Dosing and Administration

<table>
<thead>
<tr>
<th>Body weight</th>
<th>Recommended dosage form</th>
<th>Loading dose (on Day 1)</th>
<th>Maintenance dose (from Day 2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 kg to less than 40 kg</td>
<td>Veklury for injection, lyophilized powder Only</td>
<td>5 mg/kg</td>
<td>2.5 mg/kg</td>
</tr>
</tbody>
</table>

- Lyophilized powder: **100 mg** of Veklury (remdesivir) reconstituted with 19 mL of Sterile Water for Injection. The only approved dosage form of Veklury for pediatric patients weighing 3 kg to less than 40 kg is Veklury for injection (supplied as 100 mg lyophilized powder in vial).

- Further dilute to a concentration of 1.25 mg/mL using 0.9% sodium chloride
  - Small 0.9% sodium chloride infusion bags (e.g., 25, 50, or 100 mL) or an appropriately sized syringe should be used for pediatric dosing.
### Veklury (remdesivir)
Recommended Rate of Infusion-Diluted Veklury for Injection Lyophilized Powder for Pediatric Patients Weighing 3 kg to Less than 40 kg

<table>
<thead>
<tr>
<th>Infusion volume</th>
<th>Infusion time$^1$</th>
<th>Rate of infusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>100 mL</td>
<td>30 min</td>
<td>3.33 mL/min</td>
</tr>
<tr>
<td></td>
<td>60 min</td>
<td>1.67 mL/min</td>
</tr>
<tr>
<td></td>
<td>120 min</td>
<td>0.83 mL/min</td>
</tr>
<tr>
<td>50 mL</td>
<td>30 min</td>
<td>1.67 mL/min</td>
</tr>
<tr>
<td></td>
<td>60 min</td>
<td>0.83 mL/min</td>
</tr>
<tr>
<td></td>
<td>120 min</td>
<td>0.42 mL/min</td>
</tr>
<tr>
<td>25 mL</td>
<td>30 min</td>
<td>0.83 mL/min</td>
</tr>
<tr>
<td></td>
<td>60 min</td>
<td>0.42 mL/min</td>
</tr>
<tr>
<td></td>
<td>120 min</td>
<td>0.21 mL/min</td>
</tr>
<tr>
<td>7 mL</td>
<td>30 min</td>
<td>0.23 mL/min</td>
</tr>
<tr>
<td></td>
<td>60 min</td>
<td>0.12 mL/min</td>
</tr>
<tr>
<td></td>
<td>120 min</td>
<td>0.06 mL/min</td>
</tr>
</tbody>
</table>

$^1$ See section 2.6 of [Veklury (remdesivir) Prescribing Information](https://www.gilead.com/-/media/files/pdfs/medicines/COVID-19/veklury/veklury_pi.pdf)
Operational Considerations for Outpatient Veklury Administration

• Infusion schedule and hours of operation:
  ▪ Infusion requires 3 consecutive days of administration
  ▪ Infusion sites need to have appropriate hours of operation to accommodate complete infusion cycle

• Pediatric-specific infusion:
  ▪ Providers credentialed in pediatrics
  ▪ Staff trained in assessment and management of pediatric patients

• Capacity for lab testing, liver function, and prothrombin time as clinically appropriate
Post-Veklury Administration Observation

- Per Veklury prescribing information, “Monitor patients during dose administration and observe for **at least 1 hour** after intravenous infusion or subcutaneous dosing is complete”.
- Provide education on follow-up, required isolation per CDC guidelines after COVID-19 exposure or diagnosis, red flags for seeking emergency care.
- Respond to severe adverse events/anaphylaxis.
- “Discharge” patient after one-hour post-administration observation if stable and without symptoms of severe adverse reaction, otherwise consider further observation or emergency department evaluation if clinical concern.
- To report SUSPECTED ADVERSE REACTIONS, contact Gilead Sciences, Inc. at 1-800-GILEAD-5 or FDA at 1-800-FDA-1088 or MedWatch (www.fda.gov/medwatch)

Managing Adverse Reactions to Veklury

- **Veklury should only be administered** in settings in which health care providers have immediate access to medications (e.g., epinephrine) to treat a severe infusion or hypersensitivity reactions, such as anaphylaxis, and the ability to activate the emergency medical system (EMS), as necessary.

- Early identification of anaphylaxis. Symptoms may include:
  - Respiratory: hypoxia, dyspnea, wheezing, angioedema
  - Gastrointestinal: nausea, transaminase elevation
  - Cardiovascular: hypotension, hypertension, tachycardia, bradycardia
  - Skin/mucosal: rash
  - Neurologic: agitation, convulsions, altered mental status, sense of impending doom
  - Other: diaphoresis, shivering, fever
Managing Adverse Reactions to Infused Outpatient COVID Therapeutics: Medications and Equipment

• **Should be available** at all sites:
  - Epinephrine (e.g., prefilled syringe or autoinjector)
  - H1 antihistamine (e.g., diphenhydramine, cetirizine)
  - Blood pressure monitor

• **If feasible**, include at sites (not required):
  - Oxygen
  - Bronchodilator (e.g., albuterol)
  - H2 antihistamine (e.g., famotidine, cimetidine)
  - Intravenous fluids
  - Intubation kit
  - Adult-sized pocket mask with one-way valve (CPR mask)

Veklury Storage and Preparation

Administration preparation process:
• Prepare sterile infusions in a manner consistent with local laws, regulations, guidelines and policies
• Obtain new vial(s) and/or IV bags if the drug product contains any visible particulate matter
• See Prescribing Information for reconstitution instructions

Needs for space to prepare infusion:
• Dedicated preparation area for sterile preparation

Acceptable equipment for Veklury drug storage:
• Refrigerated storage (2-8 °C)
• Temperature control mechanism including temperature monitoring process

Note: product can be prepared for infusion bedside by any qualified medical professional

Official Veklury Website https://www.vekluryhcp.com/dosing-and-admin/
Veklury (remdesivir): Product Information

• FDA Approved for certain COVID19 indications, outpatient and inpatient

• Procurement/Ordering:
  ▪ Commercially available through Gilead Pharmaceuticals https://www.gilead.com/remdesivir
  ▪ Veklury is available through multiple distributors.
    • Outpatient distribution: Amerisource Bergen and Cardinal
      ▪ Non-hospital entities that can attest to the proper administration of Veklury in accordance with the label can order Veklury for outpatient use.
    • Inpatient hospital distribution: Hospitals should continue ordering Veklury through AmerisourceBergen Specialty Division, Cardinal Specialty, and McKesson Plasma & Biologics.

• Therapeutics Locator Tool include outpatients Veklury (remdesivir) providers that allows visibility of Veklury outpatient infusion sites on the HHS COVID-19 Therapeutics Locator to assist in matching patients at high risk of severe COVID-19 to the medications that can prevent disease progression https://covid-19-therapeutics-locator-dhhs.hub.arcgis.com/

• Infusion sites can opt in using simple online form. All that is needed from provider is location information and agreement to participate)
  https://protect-ows.hhs.gov/secure-upload/forms/rdhopafauktmmhqrba6ipvauk

  ▪ For provider sites that want to be removed from the locator, follow the opt in link, fill out the form and select to opt out before re-submitting. In order to opt out, please ensure you use the EXACT information previously used when provider opted in.
    https://protect-ows.hhs.gov/secure-upload/forms/rdhopafauktmmhqrba6ipvauk

• Sites are encouraged to offer outpatient Veklury, especially in collaboration with tertiary centers treating immunocompromised patients for whom Paxlovid may not be clinically appropriate (e.g., transplant centers, oncology, etc.) and for vulnerable pediatric patients not eligible for other outpatient treatments.
Example of Patient Flow for Outpatient Intravenous Product

<table>
<thead>
<tr>
<th>Pre-treatment</th>
<th>Treatment</th>
<th>Post-treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Confirm diagnosis of COVID-19 infection</td>
<td>Pre-book time for administration space and follow clear protocol for coming onsite</td>
<td>Discharge patient immediately following monitoring completion</td>
</tr>
<tr>
<td><strong>Discuss treatment with patient</strong></td>
<td>• Ensure operationally ready to receive and treat the patient</td>
<td>• Follow clear protocol to minimize risk of exposure to others</td>
</tr>
<tr>
<td>• Ensure patient meets treatment requirements and understands risks</td>
<td>• Use CDC recommended practices to minimize exposure to others</td>
<td>• Schedule subsequent appointments for Veklury and ensure patient understands importance of completing medication course</td>
</tr>
<tr>
<td><strong>Schedule the patient to come in for treatment ASAP (3 consecutive days for Veklury)</strong></td>
<td><strong>Provide treatment to patient</strong></td>
<td><strong>Post-treatment care encouraged to be via telemedicine as possible</strong></td>
</tr>
<tr>
<td>• Provide guidance on site visit protocols to patients</td>
<td>• Infusion duration up to ~1 hr(^1) with an additional 1 hr of observation post infusion (checks during infusion and observation)</td>
<td>• Normal follow-up care, no special data tracking requirements</td>
</tr>
<tr>
<td>• Provide patient education on what to expect with administration</td>
<td>• Infusion pumps or gravity-based infusion acceptable</td>
<td><strong>Ensure preparation for administration reactions as unlikely but possible side effect</strong></td>
</tr>
</tbody>
</table>

\(^1\)Contingent on product dilution, reference EUA fact sheet or prescribing information for dilution and infusion timing

Pre-treatment steps should be completed via telemedicine as possible (~30 mins)
Products for Treatment of Mild-to-Moderate COVID-19: Alternative Therapies per NIH Guidelines
Lagevrio (molnupiravir) – Merck Oral Antiviral (Alternative)

Lagevrio (molnupiravir) Product Information
https://www.molnupiravir-us.com/
Lagevrio (molnupiravir) Product Information

• FDA Fact Sheets
  - Lagevrio (molnupiravir) provider fact sheet https://www.fda.gov/media/155054/download
  - Lagevrio (molnupiravir) patient fact sheet https://www.fda.gov/media/155055/download
  - Lagevrio (molnupiravir) patient fact sheet (Spanish): N/A

• Manufacturer’s Resources:
  - Website for Healthcare Providers https://www.molnupiravir-us.com/hcp/
  - Website for Patients https://www.molnupiravir-us.com/patients/

• Safety Reporting:
  - DHCP Letter https://www.fda.gov/media/165071/download
  - Report a Pregnancy Exposure https://covid-pr.pregistry.com
  - Safety Reporting Email dpoc.usa@msd.com
Lagevrio (molnupiravir) Authorization

- Lagevrio (molnupiravir) has been authorized by FDA under an EUA, for the treatment of mild-to-moderate COVID-19 in adults who are at high-risk for progression to severe COVID-19, including hospitalization or death, for whom alternative COVID-19 outpatient treatment options approved or authorized by FDA are not accessible or clinically appropriate.

- Not authorized for:
  - Patients less than 18 years of age
  - Initiation of treatment in patients requiring hospitalization due to COVID-19
  - Use longer than 5 consecutive days

- Lagevrio (molnupiravir) may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under state law to prescribe drugs in the therapeutic class to which Lagevrio (molnupiravir) belongs (i.e., anti-infectives).

Fact Sheet for Healthcare Providers for Lagevrio (molnupiravir) https://www.fda.gov/media/155054/download
Lagevrio (molnupiravir)

Dosage and Administration

• **800 mg (four 200 mg capsules)** taken orally every 12 hours for 5 days, with or without food.

• Take Lagevrio (molnupiravir) as soon as possible after a diagnosis of COVID-19 has been made, and within 5 days of symptom onset.

• Not authorized for use for longer than 5 consecutive days.

• For administration via nasogastric (NG) or orogastric (OG) Tube (12F or larger), refer to instructions within the EUA Fact Sheet, Section 2.3

Contraindications and Precautions

• No contraindications have been identified based on the limited available data on the emergency use of Lagevrio (molnupiravir) authorized under the EUA.

• Not recommended for use during pregnancy and not authorized for use in patients under 18 years of age.

• Hypersensitivity reactions, including anaphylaxis have been reported with Lagevrio (molnupiravir).

• If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue Lagevrio (molnupiravir).
Lagevrio (molnupiravir) Checklist Tool for Prescribers

**Patient Eligibility**

- Current diagnosis of mild to moderate COVID-19
- Age ≥ 18 years
- Alternate COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate
- High-risk\(^1\) criteria met
- Symptom onset within 5 **days**\(^*\)
- Not hospitalized due to COVID-19

\(^*\)Prescriber is encouraged to include a note to the pharmacist in the prescription stating:

Please fill prescription by [insert date] This prescription fill by date is within 5 days from symptom onset and complies with the patient eligibility criteria under the EUA.

---

2. Molnupiravir Checklist Tool for Prescribers: https://www.fda.gov/media/155118/download
Prescriber Requirements – All Patients

• Provide electronic or hard copy of patient fact sheet

• Document* that patient has received an electronic or hard copy of the patient fact sheet

• Review the information contained within the patient factsheet with the patient and counsel patient on the known and potential benefits and risks of Lagevrio (molnupiravir)

• Advise patients on need for contraception use as appropriate
  • Females of childbearing potential treated: should use a reliable method of contraception correctly and consistently, as applicable, for the duration of treatment and for 4 days after the last dose of Lagevrio (molnupiravir)
  • Males of reproductive potential treated: if sexually active with females of childbearing potential, should use a reliable method of contraception correctly and consistently during treatment and for at least 3 months after the last dose

• The prescribing healthcare provider and/or the provider’s designee must report all medication errors and serious adverse events potentially related to Lagevrio (molnupiravir) within 7 calendar days from the healthcare provider’s awareness of the event

*How and where documentation occurs is at the discretion of the prescribing health care provider and their clinical site.

Molnupiravir Checklist Tool for Prescribers: https://www.fda.gov/media/155118/download
Individuals of Childbearing Potential

• Assess whether pregnant or not
  ▪ Report of last menstrual period in an individual who has regular menstrual cycles, uses a reliable method of contraception correctly and consistently or has had a negative pregnancy test
  ▪ Negative pregnancy test (recommended but not required if other criteria are not met)

• If pregnant:
  ▪ Counsel the patient regarding the known and potential benefits and potential risks of Lagevrio (molnupiravir) use during pregnancy
  ▪ Document* that the patient is aware of the known and potential benefits and potential risks of Lagevrio (molnupiravir) use during pregnancy
  ▪ Make the individual aware of the pregnancy surveillance program
  ▪ If the pregnant individual agrees to participate in the pregnancy surveillance program and allows the prescribing healthcare provider to disclose patient specific information to Merck, the prescribing healthcare provider must provide the patient’s name and contact information to Merck (at 1-877-888-4231 or pregnancyreporting.msd.com)

• If not pregnant:
  ▪ Make the individual and their partner aware of the pregnancy surveillance program and encourage them to participate should they become pregnant
  ▪ Review contraception requirements per Lagevrio Providers Fact Sheet https://www.fda.gov/media/155054/download

*How and where documentation occurs is at the discretion of the prescribing health care provider and their clinical site.
Viral RNA Rebound

- Viral RNA Rebound Post-treatment increases in SARS-CoV-2 RNA shedding levels (i.e., viral RNA rebound) in nasopharyngeal samples were observed on Day 10, Day 15, and/or Day 29 in a subset of Lagevrio and placebo recipients in the Phase 3 MOVe-OUT trial. Approximately 1% of both Lagevrio and placebo recipients had evidence of recurrent COVID-19 symptoms coinciding with a rebound in viral RNA levels in nasopharyngeal samples.

- Post-treatment viral RNA rebound was not associated with the primary clinical outcome of hospitalization or death through Day 29 following the single 5-day course of Lagevrio treatment. Post-treatment viral RNA rebound also was not associated with the detection of cell culture infectious virus in nasopharyngeal swab samples.

- Viral RNA rebound is not specific to Lagevrio or Paxlovid and has been seen in placebo recipients

***Not exclusive to Lagevrio***

Lagevrio (molnupiravir):
Product Information & Ordering Logistics

- **EUA Status:** Currently under Emergency Use Authorization from the FDA
- **Procurement:** Currently purchased and supplied by the US Government
- **Eligibility information:**
  - ASPR Lagevrio page https://aspr.hhs.gov/COVID-19/Terapeutics/Products/Lagevrio/Pages/default.aspx
  - HHS Information Sheet for Providers - Lagevrio https://aspr.hhs.gov/COVID-19/Terapeutics/Products/Lagevrio/Documents/Lagevrio-Information-Sheet.pdf
- **To order:**
- **Where to find:**
  - COVID-19 Test to Treat Locator https://aspr.hhs.gov/TestToTreat/Pages/default.aspx

Module 3: Oral Antiviral Administration
Patient Flow for Antiviral Oral Therapies
(When product not available onsite)

**Assessment and Prescribing**

- Confirm diagnosis of COVID-19 infection
- Discuss treatment with patient
  - Ensure patient meets treatment requirements and understands risks
- Prescribe therapy for patient & provide the medication fact sheet (for product under EUA)

**Visit Discharge**

- Prescription provided to the patient
  - Ensure patient understands medication therapy being provided
  - Ensure medication therapy being dispensed complies with federal/state dispensing laws
- Discuss treatment with patient
  - Ensure patient meets treatment requirements and understands risks
- Prescribe therapy for patient & provide the medication fact sheet (for product under EUA)
  - Document required patient assessment in medical record
  - Provide patient education on medication therapy being prescribed
- Determine locations medication is available in local area.

**Post-visit**

- Pharmacist receives or prescribes patient prescription
  - Pharmacy should prioritize the prescription fill and ensure timely turnaround to support same day start for therapy
  - Pharmacist verifies prescription is appropriate for patient. Any concerns are clarified with prescribing provider
- Pharmacy staff dispenses product to the patient
  - Patient is counseled on medication therapy and reminded to start immediately
- Patient to begin prescribed therapy immediately and continue x 5 days
- Patient to report any adverse effect to FDA MedWatch
  - Patients that present for hospital visit may continue their prescribed antiviral during hospitalization (at discretion of provider)

Test to Treat Locator https://aspr.hhs.gov/TestToTreat/Pages/default.aspx
Overall goal of Test to Treat program is to increase access to COVID-19 oral therapeutics, particularly for individuals who don’t have ready access to a health care provider.

COVID-19 treatments delivered as part of Test to Treat Program (Paxlovid and Lagevrio) must be taken within 5 days of initial COVID-19 symptoms.

- Helps close gap between positive COVID-19 test and receiving treatment for those eligible.

Builds upon existing distribution of oral antivirals we are already making available at no cost to thousands of locations nationwide.

An individual’s healthcare providers remain the first option for care; Test to Treat sites are one additional access point.
Test to Treat Site Locator

- Identifies all Test to Treat program sites and all sites to fill an existing prescription
  - Visibility of telehealth and home delivery options on locator
- Call center also available: 1-800-232-0233 (TTY 1-888-720-7489) to get help in English, Spanish, and more than 150 other languages—8 AM to 8 PM ET Monday through Friday, 8 AM to 5 PM ET Saturday and Sunday
- Disability Information and Access Line (DIAL) https://acl.gov/DIAL also available to specifically help those with disabilities access services. 1-888-677-1199, Monday to Friday from 8 AM to 9 PM ET or email DIAL@usaginganddisability.org.

Module 4: Reimbursement
CMS Resources

CMS Resources:


- Oral Antiviral NDC Numbers:
  - Reduced Dose (Renal) Paxlovid: 0069-1101-20
  - Lagevrio (molnupiravir): 0006-5055-06, 0006-5055-07

- Veklury (remdesivir) NDC Numbers: 61958-2901-2 (lyophilized power for injection), 61958-2902-2 (aqueous-based solution for injection)

Continue to check CMS website for most up to date information (www.CMS.gov)
CMS Resources: Veklury Billing

- CMS created HCPCS (Healthcare Common Procedure Coding System) code J0248 for Veklury
  - J0248 represents 1mg, and you should report units to reflect the dosage you administered for each patient.

- Outpatient Billing Example: a provider administering Veklury (remdesivir) in the outpatient setting would bill J0248 for the product and could use the following CPT code for its administration:

- 96365 (Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour)
  - and if needed use: 96366 (Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure).

- Medicare Part B will provide payment for the drug and its administration under the applicable Medicare Part B payment policy when you provide it in the outpatient setting, according to the FDA approval and authorization. In most cases, your patient’s yearly Part B deductible and 20% co-insurance apply.

Module 5: Additional Resources
COVID-19 Vaccination after mAb Administration

Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the US

• Non-hospitalized COVID-19 patients who previously received passive antibody therapy
  ▪ There is no longer any need to delay vaccination following receipt of monoclonal antibody or convalescent plasma beyond recovery from the acute illness (if symptoms were present) and criteria to discontinue isolation have been met.

• Hospitalized COVID-19 patients
  ▪ Follow guidelines from [CDC Advisory Committee on Immunization Practices](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#CoV-19-vaccination)
Sites with inventory of USG-purchased COVID-19 therapeutics must provide information on product utilization, wastage and stock on hand.

For sotrovimab, bam/ete, REGEN-COV, bebtelovimab, Evusheld:

- Reporting required once a month by 11:59ET pm the last day of the month

For Paxlovid and Lagevrio:

- Reporting required at least twice a month by 11:59ET pm on the 15th and last day of the month
COVID-19 Therapeutic Resources

• Administration for Strategic Preparedness and Response
  https://ASPR.HHS.gov

• For the latest information on all COVID-19 therapeutics, refer to:
  ▪ ASPR’s COVID-19 Therapeutics Resources https://aspr.hhs.gov/COVID-19/Therapeutics/Pages/default.aspx

• Still have questions? Reach out to HHS COVID 19 Therapeutics Email
covid19therapeutics@hhs.gov
Module 6:
Appendices
Appendix A: Outpatient Infusion Site Resources
Sample Staffing Models for Parenteral Therapeutic Administration

Examples of staff plans (*recommended positions may vary depending on the State’s scope of practice for Paramedics as it related to Subcutaneous and or Intravenous administration of medications or mAbs*)

- **8 - 10 bed mAb infusion/observation site**
  - 1 physician / advanced practitioner (present or available via telemedicine)
  - 2 Nurses
    - 1 Nurse or Paramedic
    - 2 Paramedics
    - 1 flex position – administrative/ logistics/ runner

- **Single station or mobile visit Subcutaneous administration site**
  - 1 physician / advanced practitioner (present or available via telemedicine)
  - 1 Nurse / Paramedic per single mobile visit or single station

Average patient (door to door) visit can range from 80-120 minutes

COVID-19 Monoclonal Antibody Therapeutics Calculator for Infusion Sites [https://www.phe.gov/emergency/mAbs-calculator/Pages/default.aspx](https://www.phe.gov/emergency/mAbs-calculator/Pages/default.aspx)
Infused Outpatient Therapeutics Site Suggested Supplies

**Infrastructure**
- Seating area with appropriate spacing for patients to receive infusion
- Steel table for product preparation
- Privacy screens if needed
- Protocol/outline for patient flow (written protocol not required however patient flow and infection control should be addressed at each administration site)
- Emergency response plan (written plan not required, however all staff should be aware of the plan for emergency response)

**General supplies**
- Infusion Reaction Kit
- Refrigerator
  - Optional to store prepared solution onsite
- Sharps container
- Biohazard disposal bag
- Trash bins and liners
- Disposable disinfecting wipes
- Hand sanitizer
- Thermometer probe covers (if required)
- 70% alcohol wipes
- Paper towels

**PPE**
- NIOSH-certified, disposable N95 filter facepiece respirators or better
- Gloves in appropriate sizes
- Gowns
- Surgical face masks for patients
- Eye and face protection (e.g., goggles, safety glasses, face shields)

**Patient Intake**
- Vital signs machine
- Pulse oximeter
- Thermometer
- Copies of eligibility checklist for treatment/PEP

**Administrative**
- Site-specific documentation
- Patient fact sheets to provide each patient (copies in English, Spanish and other appropriate languages)

**Administration Supplies-Subcutaneous**
- Alcohol wipes
- 3 or 5 mL luer lock syringes (4 required for each patient for subcutaneous administration)
- Appropriate needles for product preparation and subcutaneous administration
  - 21-gauge 1.5-inch needles for product transfer
  - 25- or 27-gauge needles for subcutaneous administration (4 per each patient course)

**Administration Supplies-Intravenous**
- IV poles
- Alcohol wipes
- 2x2 gauze pads
- Adhesive bandages
- Medical tape
- Tegaderm bio-occlusive dressing
- Absorbent underpads (blue pads)
- Normal saline bags for mixing/administration- 50-250 mL
- IV administration sets:
  - For monoclonal antibody infusion: PVC infusion set with/without DEHP containing 0.2- or 0.22-micron polyethersulfone (PES) in-line filter
  - IV catheters
  - IV extension set tubing
  - 3mL saline syringes
  - Needles – stainless steel 18ga
  - Optional: Transilluminator (vein finder)
Site Preparation for Infused Outpatient COVID-19 Therapeutic Administration

• Collect administration site location(s), address, and points of contact
  ▪ For mobile or deployed teams, identify the point of contact at the administration site and make contact
  ▪ Site will need dedicated space for isolation of COVID-19 patients¹
  ▪ Rededication of existing clinical space is permitted under the CMS Hospital Without Walls Initiative

• Ensure a patient scheduling and referral process is in place

• Identify and understand which therapeutics will be administered

• Determine who is responsible for ordering infused therapeutic administration
  ▪ Referring provider
  ▪ On-site or telemedicine provider
  ▪ Standing order

• Brief administration team with site objectives

• Team training
  ▪ Site workflow
  ▪ Therapeutic Administration
  ▪ Managing adverse reactions with rescue medications on site as applicable

Appendix B: COVID-19 Convalescent Plasma
COVID-19 Convalescent Plasma EUA¹

• Eligibility Criteria
  ▪ Adult and pediatric patients with immunosuppressive disease or receiving immunosuppressive treatment at high risk for progressing to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options authorized/approved by FDA are not accessible or clinically appropriate

• Not authorized for
  ▪ Treatment of immunocompetent patients with COVID-19 infection

• Contraindications
  ▪ Individuals with a history of severe allergic reactions or anaphylaxis to plasma transfusion

• Administration Considerations
  ▪ Administer according to standard institutional medical and nursing practices for the administration of plasma²

¹ Emergency Use Authorization of COVID-19 Convalescent Plasma https://www.fda.gov/media/141478/download
NIH Guidelines Panel- COVID-19 Convalescent Plasma

• There is insufficient evidence for the Panel to recommend either for or against the use of high-titer CCP for the treatment of COVID-19 in hospitalized or nonhospitalized patients who are immunocompromised
  ▪ Some panel members would use CCP to treat an immunocompromised patient with significant symptoms attributable to COVID-19 and with signs of active SARS-CoV-2 replication and who is having an inadequate response to available therapies. In these cases, clinicians should attempt to obtain high-titer CCP from a vaccinated donor who recently recovered from COVID-19 likely caused by a SARS-CoV-2 variant similar to the variant causing the patient’s illness
• There is insufficient evidence for the Panel to recommend either for or against the use of high-titer CCP for the treatment of COVID-19 in nonhospitalized patients who are immunocompetent
• The panel recommends against the use of CCP for the treatment of COVID-19 in hospitalized patients who are immunocompetent

Outpatient COVID-19 Convalescent Plasma (CCP) Resources

- **Emergency Use Authorization of COVID-19 Convalescent Plasma**
  [https://www.fda.gov/media/141478/download](https://www.fda.gov/media/141478/download)

- **Implementation of an Outpatient Covid-19 Convalescent Plasma Administration Program**

- **Early Outpatient Treatment for COVID-19 with Convalescent Plasma-NEJM**

- **New COVID-19 Treatments Add-On Payment (NCTAP) | CMS**
  - ICD-10-PCS Code: XW13325, XW14325 *(Only applies to inpatient use)*

- **Addendum A and Addendum B Updates | CMS**
  [https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Addendum-A-and-Addendum-B-Updates](https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Addendum-A-and-Addendum-B-Updates)
  - APC Code: 9540 / HCPCS Code: C9507 *(Only applies to outpatient use)*
Appendix C: Formerly-Authorized Products
### EUA Products Not Currently Authorized

HHS continuously monitors emerging variants to assess their potential impacts on testing, treatments and vaccines, including susceptibility to therapeutics. There is potential for paused products to play a role in addressing future COVID-19 variants. Sites are encouraged to retain all product in the event that the below authorizations change in the future. For current variant data, refer to [CDC Nowcast Projections](https://covid.cdc.gov/covid-data-tracker/#variant-proportions).

<table>
<thead>
<tr>
<th>Product</th>
<th>Latest Status</th>
<th>Links</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bebtelovimab</td>
<td>as of 30 November 2022, <a href="https://aspr.hhs.gov/COVID-19/Therapeutics/updates/Pages/important-update-30November2022.aspx">not authorized in any US region</a></td>
<td></td>
</tr>
<tr>
<td>Sotrovimab</td>
<td>as of 05 April 2022, <a href="https://aspr.hhs.gov/COVID-19/Therapeutics/updates/Pages/important-update-5April2022.aspx">not authorized in any US region</a></td>
<td></td>
</tr>
<tr>
<td>Bamlanivimab plus etesevimab</td>
<td>as of 24 January 2022, <a href="https://aspr.hhs.gov/COVID-19/Therapeutics/updates/Pages/important-update-24January2022.aspx">not authorized in any US region</a></td>
<td></td>
</tr>
<tr>
<td>Casirivimab plus imdevimab (REGEN-COV)</td>
<td>as of 24 January 2022, <a href="https://aspr.hhs.gov/COVID-19/Therapeutics/updates/Pages/important-update-24January2022.aspx">not authorized in any US region</a></td>
<td></td>
</tr>
</tbody>
</table>

[COVID-19 Therapeutic Product Expiration Database (hhs.gov)](https://aspr.hhs.gov/COVID-19/Therapeutics/Pages/Product-Expiry.aspx)
Guidelines for Product Return/Disposal

- All USG distributed COVID19 Therapeutics are property of USG and must be used in accordance with the EUA
- Sites of care cannot donate products to entities outside the U.S. or for use outside the U.S.
- Any returned product will be destroyed, as product integrity cannot be verified
- Non-expired product should not be destroyed. **No returns of product currently in distribution by the USG.**

- All sites: check first with respective state and local health department to ensure product cannot be used/stored elsewhere in the state or region
- Jurisdictions can transfer product to other jurisdictions/states/territories
- **Expiration dates are extended often**, check for updates and notices on potential pending updates on any expired or nearly expired product at [COVID-19 Therapeutic Product Expiration Database (hhs.gov)](https://aspr.hhs.gov/COVID-19/Therapeutics/Pages/Product-Expiry.aspx) before returning
- Doses discarded on-site for any reason and any doses returned **need to be recorded in HPOP**
- Upon these considerations, if undamaged product needs to be disposed of, destroy it on-site in accordance with the HPOP attestation, or follow the returns instructions below:
  - For bam and bam/ete, see [The Lilly Return Goods Procedure](https://www.lillytrade.com/), detailed guidance. https://www.lillytrade.com/
  - Bebtelovimab returns are not being accepted.
  - For REGEN-COV, call 844-734-6643
  - For sotrovimab, see the [GSK Returns Goods Policy](https://www.gsk-ecs.com) at: https://www.gsk-ecs.com
  - For Evusheld, visit [Evusheld](https://www.evusheld.com/ or call 1-833-EVUSHLD)
- Reconstituted (diluted) product SHOULD NOT be returned and should be treated as waste per your facility's SOP
On Site Destruction of Expired or Unauthorized Product

• For licensed provider locations with destruction procedures in place that follow all federal, state, and local regulations, therapeutics can be destroyed on site only if:
  ▪ Guidelines are followed on what product can be destroyed
    • Only expired product or unauthorized product that can no longer be stored
    • No unexpired product that is currently authorized for use can be destroyed
  ▪ Sites are to follow established protocols for destruction and attest in HPOP to following all regulations
  ▪ Quantities of any product destroyed is recorded in HPOP

• The established returns process for each product is still an option for sites who do not have an established method for proper destruction or otherwise prefer to go through the returns process
  ▪ Returned product must also be recorded in HPOP